Treatment resistant depression: Actuality and perspectives in 2017;Dépression résistante au traitement: Actualité et perspective en 2017

Revue Medicale de Bruxelles

Volumn 38, Issue 1, 2017, Pages 16-25

  Lucas, N ^a   Hubain, P ^b   Loas, G ^b   Jurysta, F ^c  

^a Centre Hospitalier Universitaire Ambroise Pare   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c Hospital de Jolimont   (Belgium)

Author keywords

Depressive disorder; Neurophysiology; Neurostimulation therapy; Treatment resistant depression

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BRAIN ATROPHY; CLINICAL FEATURE; CONSENSUS DEVELOPMENT; DISEASE SEVERITY; ELECTROCONVULSIVE THERAPY; GLUTAMATERGIC SYNAPSE; HUMAN; MAJOR DEPRESSION; NEUROANATOMY; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE;

EID: 85030759409     PISSN: 00353639     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Kosel M, Berney A: Dépression résistante au traitement: enjeu, thérapie et place des nouvelles approches de neurostimulation. Rev Med Suisse 2012; 8: 942-5
2. Vieta E, Colom F: Therapeutic options in treatment-resistant depression. Ann Med 2011; 43: 512-30
3. Schosser A, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S et al.: European Group for the study of resistant depression (GSRD); Where have we gone so far: Review of clinical and genetic findings. Eur Neuropsychopharmacol 2012; 22: 453-68
4. American Psychiatric Association: MINI DSM-IV-TR; Critères diagnostiques. Paris, Masson, 2004
5. Patten SB, Kennedy SH, Lam RW: Canadian Network for mood and anxiety treatment (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management. J Affect Disord 2009; 117: 5-14
6. Berlim MT, Turecki G: Definition, Assessment, and Staging of treatment-Resistant Refractory Major Depression: a review of current concept and Methods. Can J Psychiatry 2007; 52: 46-53
7. Stahl S: Psychopharmacologie essentielle: Bases neuroscientifiques et applications pratiques, 2eme édition. Paris, Lavoisier, 2010
8. Thase ME: The role of neurobiologic processes in symptoms of depression. J Clin Psychiatry 2011; 72: e08
9. Brunoni AR, Lopes M., Fregni F: A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008; 11: 1169-80
10. Taylor SM: Electroconvulsive Therapy, Brain-Derived Neurotrophic Factor, and Possible Neurorestorative Benefit of the Clinical Application of Electroconvulsive Therapy. J ECT 2008; 24: 160-5
11. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H et al.: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386-9
12. Drevets WC, Savitz J, Trimble M: The subgenual Anterior Cingulate Anterior Cingulate Cortex in Mood Disorders. CNS Spectr 2008; 13: 663-81
13. Ollat H: Neuroanatomie de la dépression majeure. Neuropsychiatrie: Tendances et débats 1998; 1: 25-7
14. Holtzheimer PE, Mayberg HS: Stuck in a Rut: rethinking depression and its Treatment. Trends Neurosci 2011; 34: 1-9
15. Shah PJ, Glabus MF, Goodwin GM, Ebmeier KP: Chronic, treatment-resistant depression and right fronto-striatal atrophy. Br J Psychiatry 2002; 180: 434-40
16. Videbech P, Ravnkilde B: Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 2004; 161: 1957-66
17. Raison CL, Miller AH: Is depression an inflammatory disorder? Curr Psychiatry Rep 2011; 13: 467-75
18. Noto C, Rizzo LB, Mansur RB, McIntyre RS, Maes M, Brietzke E: Targeting the Inflammatory Pathway as a therapeutic tool for major depression. Neuroimmunomodulation 2014; 21: 131-9
19. Jaafari N: Avancées thérapeutiques dans la dépression résistante. L'encéphale 2013; 39: 15-17
20. Furukawa TA: Assessment of mood: Guides for clinicians. J Psychosom Res 2010; 68: 581-9
21. ∗D report. Am J Psychiatry 2006; 163: 1905-17
22. Dierick M, Claes S, De Nayer A, Cosyns P, Constant E, Souery D: Manuel de psychopharmacothérapie. Gent, Academia Press, 2012
23. Mathew SJ, Shah A, Lapidus K et al.: Ketamine for Treatment-Resistant Unipolar Depression: Current Evidence. CNS Drugs 2012; 26: 189-204
24. Kellner CH, Lisanby S, Weiner R, Prudic J, Rudorfer M V, Young RC et al.: Speed of response to electroconvulsive therapy compared with ketamine. Psychiatry Res 2015; 225: 215
25. Ghasemi M, Kazemi M, Yoosefi A. et al.: Rapid antidepressant effects of repeat doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res 2014; 215: 355-61
26. Parikh SV, Segal ZV, Grigoriadis S, Ravindran AV, Kennedy SH, Lam RW et al.: Canadian network for mood and anxiety treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord 2009; 117: 15-25
27. Merkl A, Heuser I, Bajbouj M: Antidepressant electroconvulsive therapy: mechanism of action, recent advances and limitations. Exp Neurol 2009; 219: 20-6
28. Lisanby SH: Electroconvulsive therapy for depression. N Engl J Med 2007; 357: 1939-45
29. Kellner CH, Knapp RG, Petrides G, Rummans TA, Husain MM, Rasmussen K et al.: Continuation Electroconvulsive therapy vs pharmacotherapy for Relapse Prevention in Major Depression. Arch Gen Psychiatry 2006; 63: 1337-44
30. Sackeim HA, Prudic J, Devanand D P, Nobler MS, Lisanby SH, Peyser S et al.: A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry 2000; 57: 425-34
31. Lefaucheur JP, André-Obadia N, Poulet E, Devanne H, Haffen E, Londero A et al.: Recommandations françaises sur l'utilisation de la stimulation magnétique transcrânienne répétitive (rTMS): règles de sécurité et indications thérapeutiques. Neurophysiol Clin 2011; 41: 221-95
32. Kennedy SH, Milev R, Giacobbe P et al.: Canadian Network for Mood and Anxiety Treatment (CANMAT) clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. J Affect Disord 2009; 117: S44-53
33. Lam RW, Chan P, Wilkins-Ho M, Yatham LN: Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. Can J Psychiatry 2008; 53: 621-631
34. Brunoni AR, Nitsche MA, Bolognini N, Bikson M, Wagner T, Merabet L et al.: Clinical research with transcranial direct current stimulation (tDCS): challenges and future directions. Brain Stimul 2012; 5: 175-95
35. Palm U, Schiller C, Fintescu Z, Obermeier M, Keeser D, Reisinger E et al.: Transcranial direct current stimulation in treatment resistant depression: A randomized double-blind, placebo-controlled study. Brain Stimul 2012; 5: 242-51
36. Ferrucci R, Bortolomasi M, Vergari M, Tadini L, Salvoro B, Giacopuzzi M et al.: Transcranial direct current stimulation in severe, drug-resistant major depression. J Affect Disord 2009; 118: 215-19
37. Ansari S, Chaudhri K, Al Montaery KA et al.: Vagus nerve stimulation: indications and limitations. Acta Neurochir Suppl 2007; 97: 281-6
38. Rush AJ, Marangell LB, Sackeim HA et al.: Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled Acute Phase Trial. Biol Psychiatry 2005; 58: 347-54
39. Rush AJ, Sackeim HA, Marangell LB et al.: Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol psychiatry 2005; 58: 355-63
40. Coffey RJ: Deep brain stimulation devices: a brief technical history and review. Artif Organs 2009; 33: 208-20
41. Anderson RJ, Frye MA, Abulseoud OA, Lee KH, McGillivray JA, Berk M et al.: Deep brain stimulation for treatment-resistant depression: efficacy, safety and mechanisms of action. Neurosci Biobehav 2012; 36: 1920-33
42. Tye SJ, Frye MA, Lee KH: Disrupting disorder neurocircuitry: treating refractory illness with neuromodulation. Mayo Clin Proc 2009; 84: 522-35
43. Holtzheimer PE, Kelley ME, Gross RE et al.: Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch Gen Psychiatry 2012; 69: 150-8
44. Lozano AM, Mayberg HS, Giacobbe P, Hamani C, Craddock RC, Kennedy SH: Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry 2008; 64: 461-7
45. Bewernick BH, Kayser S, Sturm V, Schlaepfer TE: Long-term effects of nucleus accumbens deep brain stimulation in treatment-resistant depression: evidence for sustained efficacy. Neuropsychopharmacology 2012; 37: 1975-85
46. Bewernick BH, Hurlemann R, Matusch A, Kayser S, Grubert C, Hadrysiewicz B et al.: Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry 2010; 67: 110-6
47. Malone DA Jr, Dougherty DD, Rezai AR, Carpenter LL, Friehs GM, Eskandar EN et al.: Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry 2009; 65: 267-75